AU2013255843B2 - Pyrimidine derivatives for the treatment of bacterial diseases - Google Patents
Pyrimidine derivatives for the treatment of bacterial diseases Download PDFInfo
- Publication number
- AU2013255843B2 AU2013255843B2 AU2013255843A AU2013255843A AU2013255843B2 AU 2013255843 B2 AU2013255843 B2 AU 2013255843B2 AU 2013255843 A AU2013255843 A AU 2013255843A AU 2013255843 A AU2013255843 A AU 2013255843A AU 2013255843 B2 AU2013255843 B2 AU 2013255843B2
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- optionally substituted
- halo
- compound
- independently represent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12166140 | 2012-04-30 | ||
| EP12166140.9 | 2012-04-30 | ||
| PCT/EP2013/058980 WO2013164337A1 (en) | 2012-04-30 | 2013-04-30 | New compounds and new use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2013255843A1 AU2013255843A1 (en) | 2014-10-23 |
| AU2013255843B2 true AU2013255843B2 (en) | 2017-11-02 |
Family
ID=48430690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013255843A Ceased AU2013255843B2 (en) | 2012-04-30 | 2013-04-30 | Pyrimidine derivatives for the treatment of bacterial diseases |
Country Status (16)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR090880A1 (es) * | 2012-04-30 | 2014-12-10 | Janssen R & D Ireland | Derivados de pirimidina |
| WO2019121352A1 (en) * | 2017-12-20 | 2019-06-27 | Basf Se | Herbicidal pyrimidine compounds |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001027107A2 (en) * | 1999-10-12 | 2001-04-19 | Bristol-Myers Squibb Company | Heterocyclic sodium/proton exchange inhibitors and method |
| WO2006113704A2 (en) * | 2005-04-18 | 2006-10-26 | Neurogen Corporation | Subtituted heteroaryl cb1 antagonists |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003214110A1 (en) * | 2002-03-15 | 2003-09-29 | Ciba Specialty Chemicals Holding Inc. | 4-aminopyrimidines and their use for the antimicrobial treatment of surfaces |
| DE102004003493A1 (de) | 2004-01-23 | 2005-08-11 | Bayer Cropscience Ag | 5-Phenylpyrimidine |
| AU2009208712B2 (en) * | 2008-02-01 | 2013-03-14 | Orchid Chemicals & Pharmaceuticals Limited | Novel heterocycles |
| CA2776849A1 (en) * | 2009-11-18 | 2011-05-26 | Fab Pharma S.A.S. | Novel heterocyclic acrylamides and their use as pharmaceuticals |
| WO2011060976A1 (en) * | 2009-11-20 | 2011-05-26 | Universite De Liege | Tryptamine-derived compounds as antibacterial agents |
| JP5697685B2 (ja) * | 2009-12-18 | 2015-04-08 | バジリア ファルマスーチカ アーゲーＢａｓｉｌｅａ Ｐｈａｒｍａｃｅｕｔｉｃａ ＡＧ | 三環式抗生物質 |
| AR090880A1 (es) * | 2012-04-30 | 2014-12-10 | Janssen R & D Ireland | Derivados de pirimidina |
-
2013
- 2013-04-29 AR ARP130101454A patent/AR090880A1/es active IP Right Grant
- 2013-04-29 TW TW102115187A patent/TWI598099B/zh not_active IP Right Cessation
- 2013-04-30 CN CN201380022591.6A patent/CN104487425B/zh active Active
- 2013-04-30 US US14/397,501 patent/US9725432B2/en active Active
- 2013-04-30 EA EA201491992A patent/EA030899B1/ru not_active IP Right Cessation
- 2013-04-30 CA CA2868930A patent/CA2868930C/en active Active
- 2013-04-30 EP EP13722329.3A patent/EP2938599B1/en active Active
- 2013-04-30 AU AU2013255843A patent/AU2013255843B2/en not_active Ceased
- 2013-04-30 BR BR112014026776-6A patent/BR112014026776B1/pt not_active IP Right Cessation
- 2013-04-30 WO PCT/EP2013/058980 patent/WO2013164337A1/en not_active Ceased
- 2013-04-30 JP JP2015509418A patent/JP6349303B2/ja active Active
- 2013-04-30 ES ES13722329.3T patent/ES2676189T3/es active Active
- 2013-04-30 NZ NZ724424A patent/NZ724424A/en not_active IP Right Cessation
- 2013-04-30 KR KR1020147029515A patent/KR102186851B1/ko not_active Expired - Fee Related
- 2013-04-30 NZ NZ700507A patent/NZ700507A/en not_active IP Right Cessation
- 2013-04-30 IN IN2363MUN2014 patent/IN2014MN02363A/en unknown
- 2013-04-30 MX MX2014013165A patent/MX358189B/es active IP Right Grant
-
2017
- 2017-08-04 US US15/668,773 patent/US10221157B2/en active Active
-
2018
- 2018-03-20 JP JP2018052573A patent/JP6622839B2/ja active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001027107A2 (en) * | 1999-10-12 | 2001-04-19 | Bristol-Myers Squibb Company | Heterocyclic sodium/proton exchange inhibitors and method |
| WO2006113704A2 (en) * | 2005-04-18 | 2006-10-26 | Neurogen Corporation | Subtituted heteroaryl cb1 antagonists |
Non-Patent Citations (17)
| Title |
|---|
| CAS RN 1060376-66-0 * |
| CAS RN 1060384-06-6 * |
| CAS RN 1060386-34-6 * |
| CAS RN 1060386-99-3 * |
| CAS RN 1060392-62-2 * |
| CAS RN 1060397-21-8 * |
| CAS RN 1060406-86-1 * |
| CAS RN 1060411-28-0 * |
| CAS RN 1060429-55-1 * |
| CAS RN 1060430-47-8 * |
| CAS RN 1060431-54-0 * |
| CAS RN 1060455-88-0 * |
| CAS RN 1060928-59-7 * |
| CAS RN 1066919-16-1 * |
| CAS RN 1069789-74-7 * |
| CAS RN 1070342-60-7 * |
| European Journal of Medicinal Chemistry, 2012, 47, 24-37 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100491371C (zh) | 用作糖原合酶激酶3β抑制剂(GSK3抑制剂)的杂芳胺化合物 | |
| TWI534145B (zh) | 四氫吡啶并嘧啶衍生物 | |
| EP3019482B1 (en) | Trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors | |
| UA57780C2 (uk) | Інгібітори фактора ха, фармацетична композиція та спосіб лікування або запобігання тромбоемболічним порушенням | |
| CN119894872A (zh) | 杂芳烃、含有杂芳烃的药物组合物及其使用方法 | |
| JP2018502141A (ja) | キナゾリン及びキノリン化合物、ならびにその使用 | |
| AU2013301452B2 (en) | New antibacterial compounds | |
| CA2879623A1 (en) | Fused bicyclic azole heterocycle as inhibitors of the enzyme fabi | |
| JP4885709B2 (ja) | ピリジニルアセトニトリル類 | |
| TW200538452A (en) | Novel 4-benzimidazol-2-ylpyridazin-3-one derivatives | |
| US10221157B2 (en) | Pyrimidine derivatives for the treatment of bacterial diseases | |
| CN117279907A (zh) | 吡咯烷酮衍生物及其在医药上的应用 | |
| HK1208454B (en) | Pyrimidine derivatives for the treatment of bacterial diseases | |
| CN114539221A (zh) | 氘代2-芳杂环-3-氧-2,3-二氢哒嗪-4-甲酰胺类抑制剂及其制备方法和应用 | |
| HK1224919A1 (en) | Trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors | |
| HK1224919B (en) | Trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: JANSSEN SCIENCES IRELAND UC Free format text: FORMER APPLICANT(S): JANSSEN R&D IRELAND |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |